Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human cancer patients

Journal Article · Thu Nov 01 00:00:00 EST 1990 · Proceedings of the National Academy of Sciences of the United States of America; (United States)

DOI:https://doi.org/10.1073/pnas.87.22.8781· OSTI ID:5822267

Gatanaga, Tetsuya; Whang, Chenduen; Cappuccini, F; Lucci, III, J A; Jeffes, E W.B. ^[1]; Kohr, W ^[2]; Lentz, R ^[3]; Tomich, J ^[4]; Yamamoto, R S ^[5]; Granger, G A ^[6]

---

1. Univ. of California, Irvine (United States)
2. Genetech Inc., San Francisco, CA (United States)
3. John Kennedy Cancer Center, Indio, CA (United States)
4. Children's Hospital, Los Angeles, CA (United States)
5. Memorial Cancer Inst., Long Beach, CA (United States)
6. Univ. of California, Irvine (United States) Memorial Cancer Inst., Long Beach, CA (United States)

Serum ultrafiltrates (SUF) from human patients with different types of cancer contain a blocking factor (BF) that inhibits the cytolytic activity of human tumor necrosis factor {alpha} (TNF-{alpha}) in vitro. BF is a protein with a molecular mass of 28kDa on reducing sodium dodecyl sulfate/polyacrylamide gel electrophoresis (SDS/PAGE). The active material was purified to homogeneity by a combination of affinity chromatography, PAGE, and high-pressure liquid chromatography. Amino acid sequence analysis revealed that BF is derived from the membrane TNF receptor. Purified BF blocks the lytic activity of recombinant human and mouse TNF-{alpha} and recombinant human lymphotoxin activity of TNF-{alpha} and recombinant human lymphotoxin on murine L929 cells in vitro. However, BF inhibits the lytic activity of TNF-{alpha} more effectively than it does that of lymphotoxin. The BF also inhibits the necrotizing activity of recombinant human TNF-{alpha} when coinjected into established cutaneous Meth A tumors in BALB/c mice. The BF may have an important role in (i) the regulation and control of TNF-{alpha} and lymphotoxin activity in cancer patients, (ii) interaction between the tumor and the host antitumor mechanisms, and (iii) use of systemically administered TNF-{alpha} in clinical trials with human cancer patients.

• OSTI ID: 5822267
• Journal Information: Proceedings of the National Academy of Sciences of the United States of America; (United States), Vol. 87:22; ISSN 0027-8424
• Country of Publication: United States
• Language: English

Related Subjects

59 BASIC BIOLOGICAL SCIENCES
NEOPLASMS
NECROSIS
RECEPTORS
AMINO ACID SEQUENCE
ELECTROPHORESIS
LYSIS
MOLECULAR STRUCTURE
PATIENTS
PURIFICATION
DISEASES
MEMBRANE PROTEINS
ORGANIC COMPOUNDS
PATHOLOGICAL CHANGES
PROTEINS
550201* - Biochemistry- Tracer Techniques